COMPANY Data
Movers and SHAKERS

Ticker | AXSM (Nasdaq) |
Current Price | $74.65 ↓ -1.25 |
Market Cap | 2.79B |
Volume | 243.80k |
52wk Range | $35.44 - $109.53 |
ADVANCED MARKET DATA |

Advanced Market Data
Axsome Therapeutics Inc. (AXSM)Overview
Axsome Therapeutics Inc is a United States-based healthcare service provider. As a pre-clinical therapeutics developer, the company attends primarily to central nervous system disorders such as Alzheimer's. Its product portfolio consists of novel drugs like the AXS-02 (disodium zoledronate tetrahydrate), which is an oral, non-opioid therapeutic for chronic pain and the AXS-05, which is a fixed-dose combination of dextromethorphan and bupropion. The AXS-02 addresses pain in over three conditions, such as complex regional pain syndrome, knee osteoarthritis and chronic low back pain. The AXS-05 on the other hand, treats resistant depression and agitation in patients with Alzheimer's disease. Both the products have passed the preclinical, Phase 1 and Phase 2 stages of development.
For further details see:
New chief at Myovant SciencesAxsome Therapeutics Inc. Corporate Filings
Axsome Therapeutics Inc. Corporate Events
Axsome Therapeutics Inc. Press Releases / News Feed
Channelchek
Not available
Channelchek
No reports available